ClotCare: Blood Clots, Stroke, Heart Attack
Sunday, October 22, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Editorial Board

Alex C. Spyropoulos, MD, FACP, FCCP

Dr. Alex C. Spyropoulos

Alex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in internal medicine.

Dr. Spyropoulos is Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. As Clinical Associate Professor of Medicine and Associate Professor of Pharmacy at the University of New Mexico Health Sciences Center, he has developed a clinical thrombosis curriculum as part of the ambulatory medicine rotation. He is currently Associate Professor of Medicine at McMaster University. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and Fellow of the Royal College of Physicians, Canada.

As a disease management consultant on anticoagulation in a managed care setting, Dr. Spyropoulos has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, perioperative “bridging” for patients on chronic anticoagulation, post-operative DVT and medical inpatient prophylaxis, and protocols with regards to the use of direct thrombin inhibitors for HIT. Dr. Spyropoulos is active in assessing outcome analyses of these protocols, especially with regards to the implementation, safety, efficacy, and pharmacoeconomic indicators, and has lectured extensively both nationally and internationally on these issues.

Dr. Spyropoulos clinical and outcomes research interests include the use of LMWH for treatment of venous thromboembolic disease, the use of alternate anticoagulants in special patient populations such as malignancy and pregnancy, pharmacoeconomic evaluation of outpatient DVT treatment programs, perioperative “bridging” outcomes using anticoagulants, thromboprophylaxis in acutely-ill medical patients, and emerging anticoagulants for the treatment of venous thrombosis. His interests also include QOL and other outcomes measures in anticoagulation clinics, such as the use of patient self-testing devices for chronic anticoagulation. He has been involved as Principal Investigator, Scientific Committee member, Steering Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter outcomes and clinical studies in thrombosis. He is also a Steering Committee member of the BRIDGE study which has recently received approval from the NHLBI for funding. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a member of the Anticoagulation Forum, and co-author for the 8th ACCP Antithrombotic Guidelines and for the 2008 International Consensus Statement guidelines on periprocedural management of antithrombotic therapy. He is a reviewer for many journals including Chest, Circulation, and Journal of Thrombosis and Thrombolysis, Annals of Internal Medicine, and Archives of Internal Medicine.

Dr. Spyropoulos’ articles, letters, and editorials have been published in over 50 peer-reviewed journals including Chest, Journal of Thrombosis and Thrombolysis, Clinical Applied Thrombosis Haemostasis, Thrombosis Research, Thrombosis Haemostasis, American Journal of Cardiology, and Journal of Thrombosis Haemostasis.

Editorial Board Members

Return to Editorial Board main page
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

World Thrombosis Day - Oct. 13, 2017

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Sunday, October 22, 2017